EpiCast Report: Glaucoma - Epidemiology Forecast to 2026

  • ID: 4453164
  • Drug Pipelines
  • 44 pages
  • GlobalData
1 of 3
EpiCast Report: Glaucoma - Epidemiology Forecast to 2026

Summary

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye’s optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. In glaucoma patients, the intraocular pressure (IOP)-the normal healthy eye pressure that is achieved when the eye produces a small amount of aqueous humor while letting an equal amount of fluid out of the eye-is disturbed due to mechanical compression and/or decreased blood flow to the optic nerve, thereby leading to increased IOP.

In the 7MM, the total prevalent cases of POAG will increase from 7,224,135 cases in 2016 to 8,549,547 cases in 2026, at an Annual Growth Rate (AGR) of 1.83%. In the 7MM, the total prevalent cases of PACG will increase from 2,644,012 cases in 2016 to 3,124,740 cases in 2026, at an AGR of 1.82%. It is forecast that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of POAG and PACG during the forecast period.

The report "EpiCast Report: Glaucoma - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and global and historical trends for glaucoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of POAG and PACG, segmented by sex and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and ages 80 years and older) in these markets. In addition, this report provides a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of glaucoma clinical types NTG, pre perimetric glaucoma (PPG), and SG. The report also includes the diagnosed incident cases of acute PACG.

Scope
  • The Glaucoma EpiCast Report provides an overview of the risk factors and global trends of glaucoma in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of primary open-angle glaucoma (POAG) or primary angle-closure glaucoma (PACG), segmented by sex and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and ages 80 years and older) in these markets. In addition, this report provides a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of glaucoma clinical types normal-tension glaucoma (NTG), pre perimetric glaucoma (PPG), and secondary glaucoma (SG). The report also includes the diagnosed incident cases of acute PACG.
  • The glaucoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The Glaucoma EpiCast report will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global glaucoma market.
  • Quantify patient populations in the global glaucoma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for glaucoma therapeutics in each of the markets covered.
  • Understand the population of glaucoma clinical types NTG, PPG, and SG.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents

2 Executive Summary
2.1 Related Reports
2.2 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Total Prevalent Cases of POAG
3.4.4 Total Prevalent Cases of PACG
3.4.5 Total Prevalent Cases of NTG and PPG
3.4.6 Total Prevalent Cases of SG
3.4.7 Diagnosed Prevalent Cases
3.4.8 Diagnosed Incident Cases of Acute PACG
3.5 Epidemiological Forecast for Glaucoma (2016-2026)
3.5.1 Total Prevalent Cases of POAG
3.5.2 Age-Specific Total Prevalent Cases of POAG
3.5.3 Sex-Specific Total Prevalent Cases of POAG
3.5.4 Diagnosed Prevalent Cases of POAG
3.5.5 Total Prevalent Cases of PACG
3.5.6 Age-Specific Total Prevalent Cases of PACG
3.5.7 Sex-Specific Total Prevalent Cases of PACG
3.5.8 Diagnosed Prevalent Cases of PACG
3.5.9 Total Prevalent Cases of NTG
3.5.10 Diagnosed Prevalent Cases of NTG
3.5.11 Total Prevalent Cases of PPG
3.5.12 Diagnosed Prevalent Cases of PPG
3.5.13 Total Prevalent Cases of SG
3.5.14 Diagnosed Prevalent Cases of SG
3.5.15 Diagnosed Incident Cases of Acute PACG
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4 Appendix
4.1 Bibliography
4.2 High-Prescribing Physician Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About
4.5 Contact
4.6 Disclaimer

List of Tables
Table 1: Risk Factors and Comorbidities for Glaucoma
Table 2: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 3: 7MM, Diagnosed Prevalent Cases of POAG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 4: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 5: 7MM, Diagnosed Prevalent Cases of PACG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 6: 7MM, Total Prevalent Cases of NTG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 7: 7MM, Diagnosed Prevalent Cases of NTG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 8: 7MM, Total Prevalent Cases of PPG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 9: 7MM, Diagnosed Prevalent Cases of PPG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 10: 7MM, Total Prevalent Cases of SG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 11: 7MM, Diagnosed Prevalent Cases of SG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 12: 7MM, Diagnosed Incident Cases of Acute PACG, Both Sexes, Ages =40 Years, N, Selected Years 2016-2026
Table 13: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2017

List of Figures
Figure 1: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages =40 Years, 2016 and 2026
Figure 2: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages =40 Years, 2016 and 2026
Figure 3: 7MM, Age-Standardized Total Prevalence of POAG, Men and Women, Ages =40 Years, 2016
Figure 4: 7MM, Age-Standardized Total Prevalence of PACG, Men and Women, Ages =40 Years, 2016
Figure 5: 7MM, Sources Used to Forecast Total Prevalent Cases of POAG
Figure 6: 7MM, Sources Used to Forecast Total Prevalent Cases of PACG
Figure 7: 7MM, Sources Used to Forecast Total Prevalent Cases of NTG
Figure 8: 7MM, Sources Used to Forecast Total Prevalent Cases of PPG
Figure 9: 7MM, Sources Used to Forecast Total Prevalent Cases of SG
Figure 10: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Acute PACG
Figure 11: 7MM, Age-Specific Total Prevalent Cases of POAG, Both Sexes, Ages =40 Years, N, 2016
Figure 12: 7MM, Sex-Specific Total Prevalent Cases of POAG, Both Sexes, Ages =40 Years, N, 2016
Figure 13: 7MM, Age-Specific Total Prevalent Cases of PACG, Both Sexes, Ages =40 Years, N, 2016
Figure 14: 7MM, Sex-Specific Total Prevalent Cases of PACG, Both Sexes, Ages =40 Years, N, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll